Evaluation of neutrophil lymphocyte and platelet lymphocyte ratios according to disease activity ındex in rheumatoid arthritis

Year 2020, Volume: 3 Issue: 3, 312 - 316, 18.06.2020

Ayşe Gülşen Doğan , Mehmet Boyacıoğlu Murat Doğan

https://doi.org/10.32322/jhsm.737131

Cited By: 1

Abstract

Objective: Rheumatoid arthritis (RA) cause of unknown origin, joints and destruction; is an autoimmune, chronic, multisystemic disease. In this study, we aimed to investigate neutrophil/lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) rates and mean platelet volume (MPV) ratios in patients using methotrexate and Anti-TNF blockers in patients with rheumatoid arthritis.
Material and Method: Sixty patients with rheumatoid arthritis and a control group of 70 healthy individuals was included in this retrospective study. The patient group was divided into three groups according to DAS 28 score. ROC analysis was performed to analyze the diagnostic values of NLR and PLR parameters. All analyzes were done in 95% confidence interval and in SPSS 17.0 for Windows package program.
Resullts: Age, CRP, sedim, NLR and PLR values in the patient group; MPV levels were higher in the control group. MPV values in DAS28-I group; NLR and PLR levels were the highest in patients in the DAS28-III group.
Conclusion: NLR and PLR values have been shown as a useful marker to evaluate disease activity in RA patients. However, more comprehensive studies are needed to use MPV values as indicators of disease activity in RA patients. 

Keywords

Neutrophil-lymphocyte ratio, NLR, platelet lymphocyte ratio, PLO, rheumatoid arthritis, RA

Romatoid artritte nötrofil lenfosit ve platelet lenfosit oranlarının hastalık aktivite indeksine göre değerlendirilmesi

Abstract

Amaç: Bu çalışmanın amacı, romatoid artrit hastalarında nötrofil/lenfosit oranı (NLO),platelet lenfosit oranı (PLO) ve ortalama platelet volümü (MPV) değerlerinin hastalık aktivite skoruna (DAS 28) göre değişimini incelemektir.
Gereç ve Yöntem: Altmış romatoid artrit hastası ve 70 sağlıklı bireyden oluşmuş kontrol grubu bu retrospektif çalışmaya dâhil edildi. Hasta grubu DAS 28 skoruna göre üç gruba ayrıldı. NLO ve PLO parametrelerinin tanısal değerlerinin analizi için ROC analizi yapıldı. Tüm analizler %95 güven aralığında ve SPSS 17.0 for Windows paket programında yapıldı.
Bulgular: Yaş, CRP, sedim, NLO ve PLO değerleri hasta grubunda; MPV düzeyleri ise kontrol grubunda daha yüksekti. MPV değerleri DAS28-I grubunda; NLO ve PLO düzeyleri ise DAS28-III grubu hastalarda en yüksek düzeydeydi.
Sonuç: NLO ve PLO değerleri, RA hastalarında hastalık aktivitesini değerlendirmek için yararlı bir belirteç olarak gösterilmiştir. Bununla birlikte, RA hastalarında MPV değerlerini hastalık aktivitesinin göstergesi olarak kullanabilmek için daha kapsamlı çalışmalara ihtiyaç vardır. 

Keywords

Nötrofil lenfosit oranı, NLO, platelet lenfosit oranı, PLO, romatoid artrit, RA

References

• 1. Kwoh CK, Simms RW, Anderson LG, et al. Guidelines for the management of rheumatoid arthritis: American College of Rheumatology ad hoc Committee on Clinical Guidelines. Arthritis Rheumatism 1996; 39: 713-22.
• 2. Semble EL. Rheumatoid arthritis: new approaches for its evaluation and management. Archives Physical Med Rehabil 1995; 76: 190-201.
• 3. Lipsky PE. Romatoid Artrit. İçinde: Soy M (Çeviri editörü). Fauci AS, Langford CA (editörler). Harrison Romatoloji, 5. Baskı. İstanbul, Nobel Tıp Kitapevleri, 2007: 85-103.
• 4. Sullivan PW, Ghushchyan V, Huang XY, Globe DR. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010; 37: 544-9.
• 5. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
• 6. Van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 2014; 32: 65-74.
• 7. Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Modern Rheumatol 2016; 26: 372-6.
• 8. Şahin A, Yetişgin A, Şahin M, et al. Can mean platelet volume be a surrogate marker of inflammation in rheumatic diseases? West Indian Med J 2016; 65: 165-9.
• 9. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Prevention Biomarkers 2014; 23: 1204-12.
• 10. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008; 102. 653-7.
• 11. Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis.J Clin Lab Anal.2016; 30: 597-601.
• 12. Okamoto H, Cücej TP, Yamanaka H, et al. Moleculer aspects of rheumatoid arthritis: role of transcription factors. FEBS J 2008; 275: 4463-70.
• 13. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev Immunol 2011; 11: 519-31.
• 14. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362-6.
• 15. Kapci M, Turkdogan KA, Duman A, et al. Biomarkers in the diagnosis of acute appendicitis. JCEI 2014; 5: 250-5.
• 16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448- 454.
• 17. Uslu AU, Kucuk A, Sahin A, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis 2015; 18: 731-5.
• 18. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-41.
• 19. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: a practical review. South Med J 2005; 98: 185-91.
• 20. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008;75: 291-4.
• 21. Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, et al. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy. Rheumatol Int 2010; 30: 1125-9.